Title: The State of the Art of Nanopsychiatry for Schizophrenia Diagnostics and Treatment
Author: Radaic, A.; Martins-de-souza, D.
Is part of: Nanomedicine-Nanotechnology Biology and Medicine, v. 28, p. 102222 -
Citation: Radaic, A.; Martins-de-souza, D.; The State of the Art of Nanopsychiatry for Schizophrenia Diagnostics and Treatment. Nanomedicine-Nanotechnology Biology and Medicine, v.28, p. 102222-, 2020
Abstract: Schizophrenia is one of the top 25 causes of global diseases burdens in terms of years lived with the disease and the emotional and economical strains it imposes on the society. Several strategies have been used to treat the patients, specially using typical and atypical psychoactives. However, due to its multifactorial characteristic and patient resistance, schizophrenia is still a difficult disease to diagnose and treat. Thus, new strategies for diagnostics and treatment must be researched to optimize the efficacy and reduce the side effects of the actual therapy. Nanomedicine tries to improve low-weight molecular agents for treatment of diseases through the use of nanoscaled carriers. Among nanomedicine, nanopsychiatry specifically deals with the potential role of nanotechnology in solving psychiatry diseases problems. Therefore, the objective of this work is to provide an overview of the state of the art of nanopsychiatry in the sense of treating schizophrenia. (C) 2020 Elsevier Inc. All rights reserved.
Funding: This research was supported by the Sao Paulo Research Foundation (FAPESP) (grants #2013/08711-3, #2017/25588-1 and #2018/03673-0), and the Brazilian Coordination for the Improvement of Higher Education Personnel (CAPES) (grant #88887.200957/2018-00).